An epigenomic circulating tumor DNA (ctDNA) assay can predict recurrence in patients with resected melanoma, according to a report published by Targeted Oncology. The blood-based approach reads methylation patterns — epigenomic marks rather than mutations — to detect residual disease before it becomes clinically apparent.

For dermatologists and oncologists managing cutaneous melanoma after surgical excision, the finding addresses a persistent surveillance gap. Standard follow-up for resected melanoma relies on imaging and physical examination, which often identify recurrence only once tumors reach a measurable burden. A ctDNA assay that flags molecular evidence of residual disease earlier could sharpen decisions on adjuvant therapy enrollment and follow-up intensity.

How does an epigenomic assay differ from mutation-based ctDNA testing?

Most commercially deployed ctDNA assays interrogate tumor-specific mutations. Epigenomic assays instead analyze DNA methylation signatures shed by tumor cells into the bloodstream. Because methylation changes are abundant across the cancer genome and often conserved across tumor cells, this readout can potentially detect disease signal where mutation-panel approaches fall short — including in patients whose tumors carry few targetable alterations.

In the setting of resected melanoma, the reported data indicate the assay identified patients at risk of recurrence. The publication frames the technology as a predictive tool for post-surgical disease monitoring rather than a diagnostic for primary lesions.

What does this mean for melanoma surveillance?

Melanoma recurrence after resection remains a dominant clinical concern, particularly in higher-stage disease where the risk of distant relapse drives prognosis. Key implications for the field:

• Earlier identification of patients likely to relapse, potentially before radiographic or clinical evidence of disease
• Better selection of candidates for adjuvant systemic therapy
• A less invasive monitoring modality compared with serial imaging
• A possible tool for stratifying patients in future adjuvant trials

The report presents the assay as investigational evidence supporting recurrence prediction. Head-to-head comparisons with mutation-based ctDNA platforms, and validation of the assay's effect on survival outcomes, remain necessary before epigenomic testing enters routine melanoma follow-up pathways.

The road ahead

If prospective validation confirms the assay's predictive performance, epigenomic ctDNA could become part of structured surveillance for resected melanoma, giving clinicians a molecular earlier-warning signal to act on.